Many are written at the time of termination and some employers may over-inflate the applicant’s qualifications. Human resources will usually conduct the screening interview over the telephone, according to the Virginia etch articles on its website titled “Telephone Interviews amp; Screening”. Please consider any relevant site notices at human services.gov.au/site information when using this material. jobWhile up to five percent of the lawyers in the state are named to Super Lawyers, no more than 2.5 percent are named to the Rising Stars list. Similar to the tool used to evaluate a candidate during an interview, writing and presentation scoring rubrics are used to evaluate the applicant’s writing and/or presentations skills based on certain predetermined criteria. Perhaps the position description needs only a few adjustments. Primacy Effect is associated with “the first impression,” interviewers’ first impressions of a candidate can often play a powerful role in their subsequent assessment. Candidates who receive a rating of at least 2 speaking and 1 reading S2/R1 but less than 3 speaking and 2 readings S3/R2 will be eligible to receive a total of .25 bump-up points. The job interview will be a primary source of information about applicants.
7:22 am Virtusa completes acquisition of majority interest in Polaris Consulting & Services, updates guidance ( VRTU ) : India subsidiary, Virtusa Consulting Services Private Limited, has acquired all of the outstanding shares of Polaris Consulting & Services (BSE: POLARIS NSE: POLARIS) held by Mr. Arun Jain, founder and chairman of Polaris, Orbitech Private Limited, and certain other minority stockholders, representing an aggregate of ~51.7% of the fully diluted outstanding shares of Polaris for an average of $3.12 per share (INR 213.883 per share), for an aggregate purchase consideration of $165.89 million. Beginning on March 11, 2016, Virtusa will commence an unconditional mandatory open offer to Polaris’ public shareholders to purchase up to an additional 26% (3,4) of the outstanding shares of Polaris. Co updates guidance to include Polaris, see Q4 non-GAAP EPS $0.43-0.45 vs $0.45 Capital IQ Consensus; revs $169-172 mln vs $173.80 mln Capital IQ Consensus Estimate 7:18 am L Brands reports Feb same store sales +5.0% vs +5.0% Retail Metrics consensus (in-line with +MSD guidance) ( LB ) : 7:17 am Avalanche Biotechnologies reports Q4 results ( AAVL ) : Q4 EPS ($0.55) vs ($0.34) single analyst estimate; revs $0.96 mln vs $0.60 mln two analyst estimate. “The team has been focusing on preclinical work designed to inform our decision on the best path forward in wet-AMD, enhancing and then applying our next-generation vector discovery platform to fuel an R&D pipeline, and continuing work under our collaboration with Regeneron. We were also looking for opportunities to leverage our expertise and resources by identifying additional assets to bring into the company,” said Paul B. Cleveland, president and chief executive officer of Avalanche. “On February 1 we announced a proposed combination with Annapurna Therapeutics, a gene therapy company with four product candidates in development, including a program for the potential treatment of alpha 1 antitrypsin deficiency which is expected to be in the clinic by the end of this year and a candidate for the potential treatment of hereditary angioedema which is expected to be in the clinic in 2017. We believe that this transaction will transform Avalanche into a leading gene therapy company with an extensive pipeline.” 7:14 am Foamix reports Q4 results; FMX101 is now on track to initiate Phase III clinical trials in moderate to severe acne ( FOMX ) : FY15 net loss was $16.5 million, or $0.58 per share, basic and diluted, compared with $11.5 million or $0.79 per share, basic and diluted, for the twelve months ended December 30, 2014.
For the original version including any supplementary images or video, visit InPlay from Briefing.com – Yahoo Finance